SGX Listed Stock

HAW PAR CORP LTD (SGX:H02)


HAW PAR CORP LTD (SGX:H02) @ SGinvestors.io
SGD 12.630
+0.030 / +0.24%
Share Price as of: 2021-05-07 17:16
Market / ISIN Code: SGX Mainboard / SG1D25001158
Sector / Industry Group / Industry: Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals


Haw Par Blogger ArticlesHAW PAR CORP LTD Blogger Articles SGX Listed Haw Par (SGX:H02) Blogger Articles H02.SI Blogger Articles
Scg8866t Stockinvesting
SCG8866T
2021-04-01 15:45:23
Portfolio Review for March 2021
  Please click and read this disclaimer if you wish to continue with the contents below. For my previous portfolio review click here YTD(2021) I have made a total profit of S$40,366.60 from my equity investments(predominantly in HK) with an XIRR of 85.56%(XIRR is annualized). From my 6 years of tracking, I have made a total of S$140,009.26 from this portfolio alone. In terms of benchmarking with STI, HKSE and World index. There was a substantial pullback recently due to inflation and interest rate worries. The large difference between my XIRR and TWR is due to XIRR being annualized in nature and the price appreciation of some of my stocks recently. Portfolio composition(4 index etfs and 26 stocks): Transactions: Sold all Haw Par(SG:H
SIAS
sias
2021-03-10 10:53:31
Haw Par Corporation: A Distinguished Brand Heritage
Wee Ee Lim sees himself as the custodian of a rich and diverse legacy, one that has withstood the test of time. The 59-year-old runs SGX-listed healthcare and leisure company Haw Par Corporation, which celebrated its Golden Jubilee in 2019. The Group’s topical analgesic Tiger Balm brand, which has crossed the century-old mark, is its crown jewel. “As CEO, I take on the role of caretaker of this company and the brand for future generations,” Wee noted. “My team and I constantly remind ourselves that we are guardians, and since we have benefitted from the contributions of generations before us, we are equally committed to further build and invest in Haw Par and Tiger Balm to safeguard this legacy.” Wee is a scion of 92-year-old property and banking magnate Wee Cho Yaw, the Non-Ex
Scg8866t Stockinvesting
SCG8866T
2021-02-11 23:54:08
Portfolio Review for CNY 2021
  Please click and read this disclaimer if you wish to continue with the contents below. For my previous portfolio review click here YTD(2021) I have made a total profit of S$100,926.24 from my equity investments(predominantly in HK) with an XIRR of 2,562.89%(XIRR is annualized). From my 6 years of tracking, I have made a total of S$200,568.90 from this portfolio alone. In terms of benchmarking with STI, HKSE and World index, I seem to have made further improvements in 2021. I have started to outperform the World index. The large difference between my XIRR and TWR is due to XIRR being annualized in nature and the drastic price appreciation of some of my stocks recently. Portfolio composition(4 index etfs and 25 stocks): Transactions:Initiated a position
Dr Tee (Ein55)
Dr Tee (Ein55)
2021-01-31 01:34:45
6 Wee Cho Yaw Singapore Giant Stocks (光宗耀祖)
Mr Wee Cho Yaw (黄祖耀) is the Top 10 richest person in Singapore for decades.  An easy way of being rich is to be a long term business partner of these proven rich people through stock investing, ideally entering during COVID-19 stock crisis with discounted prices. In this article, you will learn from Dr Tee on 6 Wee Chow Yaw Family Giant Stocks in Singapore for longer term investing with COVID-19 recovery stock rally. Bonus for readers who could read every words of the entire article, learning unique strategy to position in each Wee family stocks. This investing strategy may be extended to any Top 10 richest person in any country. 1) UOB Bank (SGX: U11) 2) UOB Kay Hian (SGX: U10) 3) UOI (United Overseas Insurance) (SGX: U13) 4) UOL Group (SGX: U14) 5) UIC (
Dr Tee (Ein55)
Dr Tee (Ein55)
2020-09-27 01:13:49
11 Singapore Healthcare COVID-19 Stocks (生死关头)
Between life and money, which is more important? In this article, you will learn from Dr Tee on 11 Singapore Healthcare Giant Stocks which are efficient in making money with life as an economic moat, while some surge in prices during COVID-19 stock crisis. 1) COVID-19 “Crisis as Opportunity” Stocks Medtecs International Corporation (SGX: 546) UG Healthcare Corporation (SGX: 41A) Top Glove Corporation (SGX: BVA) Riverstone Holdings (SGX: AP4) 2) Medical Services Stocks Q&M Dental Group (SGX: QC7) Raffles Medical Group (SGX: BSL) 3) Healthcare Products Stocks Tianjin Zhong Xin Pharmaceutical Group (SGX: T14) Haw Par Corporation (SGX: H02) 4) Healthcare REITs First Reit (SGX: AW9U) ParkwayLife Reit (SGX: C2PU) IHH Healthcare (SGX: Q0F)





Investment BloggerSG Investment BlogSG Invest BloggersBloggers Say








Your Say











Stock / REIT Search

Advertisement

Advertisement